Newsroom

New opportunities to treat opportunistic infections

By Sarah Anderson, PhD

In the current era of the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic, those with HIV/AIDS are often said to “die with the virus, not of it.” 

The phrase refers to the fact that, while there is no cure, the advent of antiretroviral therapy (ART) medication that stops the virus from replicating has allowed many people with HIV/AIDS to lead long and healthy lives. 

But the sentiment has a sinister undertone, hinting at the reality that, for those with poorly managed HIV/AIDS, the cause of death is generally not the virus itself, but rather a secondary infection. Bacteria, fungi, and viruses recognize a breach in the host’s immune defenses and seize the opportunity to infect, making these individuals particularly susceptible to conditions such as cryptococcal meningitis, pneumocystis pneumonia, toxoplasmosis, listeriosis, and viral hepatitis.  

Combatting these opportunistic infections is the focus of a trio of recent studies, conducted by researchers in the lab of Dr. Jim Kronstad, a professor in UBC’s Department of Microbiology and Immunology, Michael Smith Laboratories, and Faculty of Land Food Systems, and Dr. Wilf Jefferies, a professor in UBC’s Department of Microbiology and Immunology, Michael Smith Laboratories, Department of Medical Genetics, Centre for Blood Research, Djavad Mowafaghian Centre for Brain Health, and Department of Urologic Sciences. The teams take unique, complementary approaches, with Dr. Kronstad’s group targeting a protein complex in Cryptococcus neoformans, a prevalent fungal pathogen affecting immunocompromised people, and Dr. Jefferies’s group homing in on a critical HIV gene. Their efforts pave the way for new strategies to tackle opportunistic infections from all angles.  

The sugar-coated killer

Researchers in the Kronstad lab are working to kickstart new ways to eliminate one particularly widespread opportunistic fungus. Cryptococcus neoformans — classified as a “critical” concern on the World Health Organization’s Fungal Priority Pathogen List — is found everywhere from soil to decaying wood to pigeon droppings, and people can become exposed by inhaling airborne spores in their environment. But while a healthy immune system will typically clear out the fungus before infection can take hold, those with HIV/AIDS and other conditions that compromise the immune response can develop cryptococcal meningitis, a potentially fatal swelling of the lining of the brain. In fact, people with HIV/AIDS account for 80 to 90 percent of cryptococcal meningitis cases. 

Unfortunately, C. neoformans is as difficult to treat as it is ubiquitous. Nicknamed the “sugar-coated killer,” the fungus is surrounded by a protective polysaccharide capsule that shields it from being detected and destroyed. In the search for antifungal drugs that can dismantle this capsule, researchers have had to grapple with the inconvenient fact that fungi are surprisingly similar to mammals in their basic biology.

“Anything that can hurt fungi also has the potential to hurt us, so drug toxicity represents a major challenge when it comes to treating fungal infections,” said Dr. Kabir Bhalla, a postdoctoral researcher in the Kronstad lab.

Scientists have discovered a handful of antifungal drugs (e.g. the azole family) that target cellular components or processes that are unique to fungi. However, fast-evolving fungi are quick to develop resistance to these drugs, and the fact that the same class of fungicides are often used to kill fungal pests in the crop fields and treat fungal infections in the human body only exacerbates this issue. 

Given these hurdles, it is critical to identify new drug targets that can expand the toolbox for treating C. neoformans infections. In a pair of recent studies published in Infection and Immunity, Dr. Bhalla and co-first author and research associate Dr. Eddy Sánchez-León investigated the potential of inhibiting the fungus’s adaptor protein-1 (AP-1) complex. 

Dr. Kabir Bhalla (left) and Dr. Eddy Sánchez-León (right)

Two large, one medium, and one small— what sounds like a group coffee order is actually the sizes of the four protein subunits that make up AP-1. These subunits work together to sort large molecules and send them to different locations throughout the cell. The researchers hypothesized that this function might be key to the growth and survival of C. neoformans and recognized that, because AP-1 is structurally distinct in fungi and humans, it may be possible to specifically target the fungal version without toxic side effects.

The researchers first deleted the genes corresponding to each of the four AP-1 subunits, creating four fungal mutants. When they examined these fungi under the microscope, they observed that they were smaller, slower-growing, and irregularly shaped, with loss of the large and medium subunits having a more dramatic effect than loss of the small one. This finding suggests that interfering with the AP-1 complex’s subunits impairs its ability to ship proteins, sugars, and other large molecules to the cell surface, compromising the integrity of the cell wall and polysaccharide capsule.  

Scanning electron microscopy images of Cryptococcus neoformans. The unmodified fungus is shown on the left, while the mutant fungus lacking the large subunit of the AP-1 complex is shown on the right. (Image credit: Dr. Kabir Bhalla, Kronstad lab)

The team then asked what these differences might mean in the context of infection. As the body’s first line of defense, C. neoformans is engulfed by macrophage immune cells, but the fungus may thwart the macrophage’s attempts to kill it and persist within the cell.

When the researchers infected macrophages with their C. neoformans mutants, they observed that loss of each AP-1 subunit reduced the fungus’s ability to survive within the cell. “That was a key experiment that motivated us to go further and evaluate these fungi in animal models,” said Dr. Sánchez-León.

In a murine infection model, exposure to mutants lacking the large and medium subunits resulted in no evidence of disease, indicating that the infection was rapidly cleared. In contrast, exposure to the mutant lacking the small subunit was associated with granulomas in the lungs — structures in which the fungal infection is sequestered, but could later reactivate.

Together, these results indicate that while the large and medium AP-1 subunits are required for C. neoformans to establish infection, the role of the small subunit is more complex. “The big breakthrough in this work is that these subunits are doing very different things,” said Dr. Bhalla. “It’s important to be thorough and dig deeper into each of these individual components in order to fully understand their unique contributions.” The researchers hypothesize that the AP-1 complex remains at least partially functional in the absence of the small subunit, but not the medium and large ones. 

Overall, these findings suggest that inhibiting one or more of these subunits is a promising approach to combating C. neoformans infections in immunocompromised people.

“We don’t have these drugs right now, but we are in an era where we can think about designing them, likely using computational biology,” said Dr. Sánchez-León. These computational tools could help researchers develop compounds that selectively bind to fungal AP-1 proteins over their mammalian counterparts. 

The team is also interested in identifying which large molecules AP-1 helps to sort and send to the cell surface and investigating if AP-1 processes proteins that are involved in regulating the immune response. As they pursue these lines of inquiry, they hope to continue to collaborate with Dr. Elitza Tocheva’s team to conduct high-resolution microscopy studies. 

The Nef big thing 

Researchers in Dr. Jefferies’s lab have focused their efforts on the HIV virus itself. His team has a decades-long track record of studying how solitary viral genes can weaken a host’s immune system — a research theme that eventually led them to Nef. When a cell is first infected with HIV, one of the virus’s genes instructs the cell to make the Nef protein, which doesn’t act as an enzyme that converts one molecule to another, but rather binds to other proteins. Through these protein-protein interactions, Nef interferes with several critical immune processes, leading researchers to suspect that it plays a key role in disarming protective immune responses.

“Is Nef alone sufficient to open the immunological hole through which opportunistic pathogens enter?” said Dr. Jefferies. 

Dr. Wilf Jefferies

The team explored this question in a recent study published in Heliyon. They genetically engineered mice to produce the Nef protein in T cells, macrophages, and dendritic cells, which are the types of cells that HIV infects. This approach allowed them to trace their findings back to Nef specifically and to circumvent a common issue in HIV research, which is that the virus does not infect mouse cells. The authors emphasize, however, that their model examines the effects of the isolated Nef protein, not the full virus, and does not capture the dynamic nature of active infection. 

The researchers observed that expressing Nef in this way drastically remodeled the immune system in the mice, decreasing the production of CD4+ T cells in immune structures throughout the body. 

To investigate the mice’s susceptibility to opportunistic viruses, which represent a major source of morbidity for people with HIV/AIDS, the researchers infected the mice with Vesicular Stomatitis Virus (VSV). While cytotoxic T lymphocyte immune cells typically rip apart cells harboring VSV, this cell-destroying response was significantly impaired in the Nef-expressing mice. The team discovered that it was not the number of cytotoxic T lymphocytes, but rather their antiviral function, that was diminished.

Next, the researchers infected the mice with Listeria monocytogenes, the bacterium responsible for listeriosis, which is 100 to 300 times more prevalent in people with HIV/AIDS than the general population. While they again observed that cytotoxic T lymphocytes were not as capable at destroying listeria-infected cells, the mice were still able to get rid of the bacteria. 

The team then decided to re-infect the mice with a second round of listeria, since people with HIV/AIDS often experience recurrent opportunistic infections. This time, they found that the mice could not clear the infection, indicating that the immune system failed to recall how to respond to L. monocytogenes. This recall response is dependent upon help from CD4+ T cells, suggesting that Nef impairs immunological memory by shrinking this immune cell population.  

These results indicate that Nef alone is indeed capable of weakening immune responses to two unrelated pathogens. “Without Nef, many of these opportunistic infections would be contained by an otherwise intact immune system; with Nef, they have the potential to become a proximate cause of mortality,” said Dr. Jefferies. This insight moves Nef from an interesting immune-modifying protein to a viable avenue for therapeutic intervention. “‘Immune dysfunction’ in HIV is a broad phrase, and broad phrases are poor drug targets. Our data have narrowed it down considerably,” Dr. Jefferies added.  

The study’s findings suggests that drugs that selectively bind to and degrade the Nef protein or block its downstream protein-protein interactions are promising strategies to restore immune function. Furthermore, by identifying the hallmarks of Nef-based immune reprogramming in mouse models, the team hopes that their work will help other researchers developing Nef-targeting therapeutics better understand what to measure when testing these drugs.  

The team envisions that these Nef-directed therapeutics may be combined with drugs that directly kill the opportunistic pathogen (antibiotics, antifungals, etc.). They expect that this approach would be most effective for pathogens that exploit the specific immune vulnerability that Nef creates: impaired cell-destroying and immune recall activity. 

Determining which pathogens fall under that umbrella is a subject of future studies, as is pinpointing the precise cellular processes through which Nef dampens the immune response. Additionally, the researchers would like to further explore the unexpected observation that Nef could interfere with the quality of immune cell function without necessarily changing the quantity of immune cells present.

Since immune status in people with HIV is often assessed via cell counts and other numerical metrics, this finding could have major implications if it holds true in humans. “If it does, it changes what we should be measuring in the clinic,” said Dr. Jefferies. “Building functional readouts into these tests may provide a more complete and accurate picture of immune health.” 

While both research projects are still in their early stages, Dr. Jefferies’s and Dr. Kronstad’s teams hope that their findings will lay the groundwork for new approaches to mitigate the disproportionate effects of opportunistic infections for those with HIV/AIDS.

“Many have been tempted to treat this as a solved historical problem; it is not,” said Dr. Jefferies. “We hope to make a difference for patients, whose clinical burden continues to be shaped not only by the virus itself, but by the spectrum of opportunistic pathogens that an immunocompromised host fails to contain.” 

 

This story was originally published by the UBC Department of Microbiology and Immunology